Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Somatostatin Receptor Positive”

59 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 59 results

Early research (Phase 1)Active Not RecruitingNCT04750954
What this trial is testing

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Neoplasm
National Cancer Institute (NCI) 29
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Large-scale testing (Phase 3)Study completedNCT03673943
What this trial is testing

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Who this might be right for
Neuroendocrine Tumors
Radiomedix, Inc. 63
Early research (Phase 1)Study completedNCT06122610
What this trial is testing

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsSomatostatin Receptor-positive Neuroendocrine Tumor
University of Wisconsin, Madison 4
Large-scale testing (Phase 3)Looking for participantsNCT06398444
What this trial is testing

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Who this might be right for
Advanced Neuroendocrine Neoplasm
Sinotau Pharmaceutical Group 85
Large-scale testing (Phase 3)Looking for participantsNCT05749289
What this trial is testing

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

Who this might be right for
SSTR Positive Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 400
Early research (Phase 1)Active Not RecruitingNCT04234568
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Who this might be right for
Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 31
Not applicableNo Longer AvailableNCT01980732
What this trial is testing

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Who this might be right for
Carcinoid TumorsIslet Cell (Pancreatic NET)Other Neuroendocrine Tumors
Andrei Iagaru
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Early research (Phase 1)Active Not RecruitingNCT05249114
What this trial is testing

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Providence Health & Services 6
Large-scale testing (Phase 3)Looking for participantsNCT06784752
What this trial is testing

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Who this might be right for
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals 240
Testing effectiveness (Phase 2)Active Not RecruitingNCT05724108
What this trial is testing

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Who this might be right for
Metastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 94
Not applicableStudy completedNCT04727723
What this trial is testing

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 164
Testing effectiveness (Phase 2)Looking for participantsNCT06427798
What this trial is testing

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Who this might be right for
Somatostatin Receptor PositiveGastrointestinal Neuroendocrine TumorsPheochromocytoma+1 more
National Cancer Institute (NCI) 66
Testing effectiveness (Phase 2)Study completedNCT03273712
What this trial is testing

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

Who this might be right for
Neuroendocrine TumorsMeningiomaNeuroblastoma+1 more
University of Iowa 39
Early research (Phase 1)Looking for participantsNCT06479811
What this trial is testing

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Who this might be right for
Sinonasal Neuroendocrine CarcinomaNasopharyngeal CarcinomaEsthesioneuroblastoma+7 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT04711135
What this trial is testing

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorsPheochromocytomaParaganglioma
Advanced Accelerator Applications 11
Early research (Phase 1)Ended earlyNCT02359500
What this trial is testing

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Who this might be right for
Neuroendocrine TumorsCarcinoid Tumors
Lale Kostakoglu 71
Testing effectiveness (Phase 2)WithdrawnNCT04106843
What this trial is testing

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Who this might be right for
Locally Advanced Adrenal Gland PheochromocytomaLocally Advanced ParagangliomaMetastatic Adrenal Gland Pheochromocytoma+11 more
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Looking for participantsNCT07057622
What this trial is testing

A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

Who this might be right for
NETS Ga68 Lu177
HTA Co., Ltd. 184
Next Page